annual total liabilities:
$413.82M+$223.55M(+117.50%)Summary
- As of today (June 28, 2025), RXRX annual total liabilities is $413.82 million, with the most recent change of +$223.55 million (+117.50%) on December 31, 2024.
- During the last 3 years, RXRX annual total liabilities has risen by +$346.41 million (+513.91%).
- RXRX annual total liabilities is now -18.04% below its all-time high of $504.87 million, reached on December 31, 2020.
Performance
RXRX Total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly total liabilities:
$371.29M-$42.53M(-10.28%)Summary
- As of today (June 28, 2025), RXRX quarterly total liabilities is $371.29 million, with the most recent change of -$42.53 million (-10.28%) on March 31, 2025.
- Over the past year, RXRX quarterly total liabilities has increased by +$214.59 million (+136.95%).
- RXRX quarterly total liabilities is now -26.47% below its all-time high of $504.97 million, reached on March 31, 2021.
Performance
RXRX quarterly total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
RXRX Total liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +117.5% | +136.9% |
| 3 y3 years | +513.9% | +54.2% |
| 5 y5 years | +83.3% | - |
RXRX Total liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +513.9% | -10.3% | +136.9% |
| 5 y | 5-year | -18.0% | +513.9% | -26.5% | +564.5% |
| alltime | all time | -18.0% | +513.9% | -26.5% | +564.5% |
RXRX Total liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $371.29M(-10.3%) |
| Dec 2024 | $413.82M(+117.5%) | $413.82M(+104.9%) |
| Sep 2024 | - | $201.94M(+5.5%) |
| Jun 2024 | - | $191.41M(+22.2%) |
| Mar 2024 | - | $156.70M(-17.6%) |
| Dec 2023 | $190.26M(-11.7%) | $190.26M(-1.3%) |
| Sep 2023 | - | $192.86M(-2.5%) |
| Jun 2023 | - | $197.74M(+0.3%) |
| Mar 2023 | - | $197.19M(-8.5%) |
| Dec 2022 | $215.48M | $215.48M(-3.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $223.50M(-4.9%) |
| Jun 2022 | - | $234.94M(-2.4%) |
| Mar 2022 | - | $240.75M(+257.2%) |
| Dec 2021 | $67.41M(-86.6%) | $67.41M(+13.1%) |
| Sep 2021 | - | $59.57M(+6.6%) |
| Jun 2021 | - | $55.88M(-88.9%) |
| Mar 2021 | - | $504.97M(+0.0%) |
| Dec 2020 | $504.87M(+123.7%) | - |
| Dec 2020 | - | $504.87M |
| Dec 2019 | $225.70M | - |
FAQ
- What is Recursion Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual total liabilities year-on-year change?
- What is Recursion Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly total liabilities year-on-year change?
What is Recursion Pharmaceuticals annual total liabilities?
The current annual total liabilities of RXRX is $413.82M
What is the all time high annual total liabilities for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual total liabilities is $504.87M
What is Recursion Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, RXRX annual total liabilities has changed by +$223.55M (+117.50%)
What is Recursion Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of RXRX is $371.29M
What is the all time high quarterly total liabilities for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly total liabilities is $504.97M
What is Recursion Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, RXRX quarterly total liabilities has changed by +$214.59M (+136.95%)